Levetiracetam Sandoz

Levetiracetam, the active ingredient in Levetiracetam Sandoz, is an Anticonvulsant presented as an oral tablet for oral use. It is indicated for the treatment of partial, generalized tonic‑clonic and myoclonic seizures in patients with epilepsy. The medication works by modulating neuronal activity and is approved for use across the European Union.

GNH USA supplies Levetiracetam Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality assurance through rigorous testing and regulatory compliance.

Levetiracetam is an anticonvulsant used to control seizure activity in various epilepsy syndromes, targeting both focal and generalized seizure types.

Partial seizures: decreases frequency of focal seizure episodes in patients with focal epilepsy. Generalized tonic‑clonic seizures: reduces occurrence of bilateral convulsive seizures in patients with generalized epilepsy. Myoclonic seizures: helps control rapid, brief muscle jerks in patients with myoclonic epilepsy.

Levetiracetam may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness - Somnolence - Fatigue - Irritability

Serious or Rare Side Effects: - Severe allergic reactions, including anaphylaxis - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal thoughts or behavior

Levetiracetam requires careful consideration in several clinical situations. - Renal impairment: dose adjustment may be necessary based on renal function. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Psychiatric symptoms: observe for mood changes, depression, or agitation. - Pregnancy: risk category unknown; discuss potential benefits and risks with a healthcare professional. - Concomitant antiepileptic use: monitor for additive effects or altered plasma levels. - Store at ambient temperature: keep in the original container, protect from moisture.

Levetiracetam can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma concentrations. - Phenytoin: may lower levetiracetam levels, reducing seizure control. - Phenobarbital: can decrease levetiracetam exposure, potentially compromising effectiveness.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam concentrations, requiring observation. - Topiramate: additive central nervous system depression may occur. - Alcohol: can enhance sedation and dizziness when combined with levetiracetam.